Subsequent response to atogepant in individuals with episodic migraine after an initial inadequate response: Post hoc analyses of a 12-week phase 3 trial

被引：0
|
作者：
Dodick, D. W. [1 ]
Nahas, S. J. [2 ]
Pozo-Rosich, P. [3 ,4 ]
Bilchik, T. R. [5 ]
McAllister, P. [6 ]
Finnegan, M. [7 ]
Ma, J. [7 ]
Chalermpalanupap, T. [7 ]
Dabruzzo, B. L. [8 ]
Lipton, R. B. [9 ]
机构：
[1] Mayo Clin, Dept Neurol, Scottsdale, AZ USA
[2] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[3] Vall Hebron Univ Hosp & Inst Res, Dept Neurol, Headache Unit, Barcelona, Spain
[4] Univ Autonoma Barcelona, Barcelona, Spain
[5] Yale Sch Med, New Haven, CT USA
[6] New England Inst Neurol & Headache, Stamford, CT USA
[7] AbbVie Inc, Madison, NJ USA
[8] AbbVie Inc, Madison, NJ USA
[9] Albert Einstein Coll Med, Bronx, NY 10467 USA
来源：
HEADACHE | 2022年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-200
引用
收藏
页码：164 / 165
页数：2
相关论文
共 50 条
  • [1] Subsequent Response to Atogepant in Individuals with Episodic Migraine after an Initial Inadequate Response: Post Hoc Analysis of a 12-week Phase 3 Trial
    Dodick, D.
    Nahas, S.
    Pozo-Rosich, P.
    Bilchik, T.
    McAllister, P.
    Finnegan, M.
    Ma, J.
    Chalermpalanupap, T.
    Dabruzzo, B.
    Lipton, R.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [2] Sustained Response to Atogepant in Individuals with Episodic Migraine: Post Hoc Analyses of 12-and 52-Week Phase 3 Trials
    Lipton, R.
    Nahas, S.
    Pozo-Rosich, P.
    Bilchik, T.
    McAllister, P.
    Finnegan, M.
    Ma, J.
    Chalermpalanupap, T.
    Dabruzzo, B.
    Dodick, D.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [3] Sustained response to atogepant in individuals with episodic migraine: Post hoc analyses of 12-and 52-week phase 3 trials
    Lipton, R. B.
    Nahas, S. J.
    Pozo-Rosich, P.
    Bilchik, T. R.
    McAllister, P.
    Finnegan, M.
    Ma, J.
    Chalermpalanupap, T.
    Dabruzzo, B. L.
    Dodick, D. W.
    [J]. HEADACHE, 2022, 62 : 165 - 166
  • [4] Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial
    Lipton, Richard B.
    Nahas, Stephanie J.
    Pozo-Rosich, Patricia
    Bilchik, Tanya
    McAllister, Peter
    Finnegan, Michelle
    Liu, Yingyi
    Chalermpalanupap, Natty
    Dabruzzo, Brett
    Dodick, David W.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2024, 25 (01):
  • [5] Sustained response to atogepant in individuals with episodic migraine and prior inadequate response to preventive treatment and in individuals with chronic migraine: post-hoc analyses from ELEVATE and PROGRESS
    Lipton, R. B.
    Chalermpalanupap, N.
    Tatsuoka, Y.
    Nagy, K.
    Liu, Y.
    Carr, K.
    McAllister, P.
    Nahas, S. J.
    Trugman, J. M.
    Sacco, S.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [6] Sustained and Subsequent Response to Atogepant Among Individuals With Episodic Migraine With Prior Treatment Failure: Post Hoc Analysis of the ELEVATE Trial
    Sacco, Simona
    Nagy, Krisztian
    Chalermpalanupap, Natty
    Vernieri, Fabrizio
    Smith, Jonathan H.
    Holle-Lee, Dagny
    Liu, Yingyi
    Carr, Karen
    Pozo-Rosich, Patricia
    Lipton, Richard B.
    [J]. CEPHALALGIA, 2023, 43 (1supp) : 265 - 266
  • [7] Sustained and Subsequent Response to Atogepant Among Individuals With Chronic Migraine: Post Hoc Analysis of the PROGRESS Trial
    Lipton, R.
    Chalermpalanupap, N.
    Nahas-Geiger, S.
    Pozo-Rosich, P.
    McAllister, P.
    Tatsuoka, Y.
    Liu, Y.
    Dabruzzo, B.
    Smith, J.
    Bilchik, T.
    [J]. HEADACHE, 2023, 63 : 168 - 169
  • [8] Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Li, Y.
    Severt, L.
    Stokes, J.
    Gandhi, P.
    Dodick, D. W.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 106 - 107
  • [9] Atogepant improved patient-reported migraine-specific quality of life in a 12-week phase 3 (ADVANCE) trial for preventive treatment of migraine
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Li, Y.
    Severt, L.
    Stokes, J.
    Gandhi, P.
    Dodick, D. W.
    [J]. HEADACHE, 2021, 61 : 43 - 44
  • [10] Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Li, Y.
    Severt, L.
    Stokes, J.
    Gandhi, P.
    Dodick, D. W.
    [J]. CEPHALALGIA, 2021, 41 (1_SUPPL) : 158 - 159
12345